Manuka Performance
Four Pillar Value Architecture

From Honey
to a Bioactive
Intelligence
Platform

A strategic deep-dive on how four integrated pillars build, reinforce and compound toward a capital value event — for experienced financial strategists and global structure advisors.

$373M
Long-Range Global Revenue Target (USD)
10–20×
IP / Data vs CPG (3–5×) Multiple Shift
4
Mutually Reinforcing Commercial Pillars
NZD $70M
Series A Target Valuation (18–24 months)
BIOACTIVE
PLATFORM
VALUE
P1
CPG & Consumer
P2
B2B Ingredients
P4
Bioactive Intelligence
P3
R&D & Clinical Science

Each pillar feeds the centre — and each other. Platform value emerges from convergence.

Commercial Architecture

The Value Waterfall

How each pillar contributes to the cumulative platform, from early consumer revenue through to a capital-scale exit. Read as a stacked value creation sequence — each stage makes the next larger and more defensible.

STAGE
EARLY
SCALE
GROWTH
PLATFORM / EXIT
STRATEGIC RATIONALE
P1 — CPG Consumer Products
P1 Revenue · Early $1.5M → Long-range $160M USD
Revenue engine and proof layer. Amazon + D2C establishes demand, provides first-party data, enables B2B conversion. Scales from $1.5M USD to $160M+ USD (USA + Korea + China + GCC) as the brand matures.
↳ Data Signal to P4
Consumer behavioural data → PolySure™ efficacy intelligence
Consumer purchase + repeat rate data feeds the PolySure™ bioactive efficacy loop. Real-world dosage data informs clinical protocol design (P3).
P2 — B2B Ingredients & IP
P2 Activated from Scale Phase · Grows to $60M+ USD
Ingredient supply to global brands. Initially unlocked by P1 consumer proof. High-margin, contracted revenue growing toward $60M+ (ingredient licensing + co-development). 65–75% gross margin.
↳ IP + Certification Feed to P4
CoA + formulation data → Bioactive Intelligence database
Every B2B partnership generates CoA data, certifications, and formulation records — structural database assets for the Bioactive Intelligence platform.
P3 — R&D, Clinical & Science
Grant-funded + commercial reinvestment. Claims + IP engine.
Continuous from launch. BSI/AgResearch SSIF Flagship 2, MPI Māori Agribusiness Fund. Ethics-approved trials: sports, gut, immune. Generates claims defensibility and IP. Funded via grants + commercial reinvestment.
↳ Claims → P1 premiumisation
Clinical outcomes → premium claims defensibility → margin
Clinical outcomes directly increase P1 CPG margin by enabling label claims and reducing CAC through authority positioning.
P4 — Bioactive Intelligence Platform
Activated at Growth Phase · Platform shifts multiple to 10–20×
Platform layer activated once data mass reaches critical volume. PolySure™ database + Kete Rāraunga + AI predictive formulation. Valuation shift: CPG 3–5× → Data/IP 10–20×. Licensing + SaaS + data partnerships.
↳ Data licensing + SaaS revenue
PolySure™ global licensing + SaaS · Recurring high-margin revenue
Stand-alone revenue stream: PolySure™ licensing to ingredient suppliers, food manufacturers, wellness brands globally. SaaS-style recurring revenue improving NRR and reducing churn risk.
PLATFORM CONVERGENCE VALUE
$373M target revenue · 10–20× multiple → $3.7B–$7.4B platform value thesis
When all four pillars are operating and feeding the platform data layer, valuation converges on: $373M long-range revenue base × 10–20× data multiple = $3.7B–$7.4B potential platform value. Unicorn trajectory supported by CPG cashflow foundation.
Capital Value Event / Exit
Acquisition · Licensing Roll-up · IPO · Partial Division Exit
Four validated exit pathways: (1) Strategic acquisition by global CPG/nutrition major, (2) PolySure™ IP licensing roll-up, (3) NZX/ASX/NASDAQ IPO at platform scale, (4) Partial exits on B2B ingredient division or platform division separately.

Strategic rationale shown alongside each stage. Revenue figures are USD. Long-range targets from the 6-Year Global Forecast. Dashed bars represent non-revenue value flows.

Pillar Deep Dive

Commercial Architecture by Pillar

Each pillar carries its own P&L logic, channel mix, margin profile, and contribution to the broader platform. These are not cost centres — they are compounding commercial assets.

PILLAR 01
High-Value Nutraceutical CPG Products
~58%
Gross Margin
$10M
Y3 US Revenue
$160M+
Y6 Global Target

The demand engine and proof layer. Amazon FBA + D2C generates first-party purchase data, repeat-use validation, and ambassador-backed brand equity. This pillar operates like a CPG business — but with IP-grade differentiation through PolySure™ batch-certified polyphenol guarantees on every SKU. Hero products: LiquidFuel, LiquidGold, GI-PRO.

Behind the current hero SKU range sits a significant NPD pipeline spanning human-targeted health, lifestyle, and sports applications. This includes emerging GLP-1 adjacent formulations targeting metabolic health and satiety — one of the highest-growth categories in global nutraceuticals — as well as condition-specific lifestyle products across cognitive performance, recovery, and longevity. Alongside human health, MPL is actively developing high-growth animal health categories, leveraging the same validated bioactive matrices and PolySure™ certification infrastructure to serve premium companion animal and performance animal markets. Each new product category deepens the platform data asset and expands the addressable market without requiring new supply chain infrastructure.

Revenue Channels & Margin
  • Amazon FBA (US primary launch) 60% rev mix Y1 · 39% Y3 — ~35% net margin after fees
  • D2C E-commerce (own platform) 40% rev mix Y1 · 26% Y3 — 58–78% blended gross margin
  • South Korea (existing export pipeline) $190K Y1 → $20.5M Y6
  • China nutraceuticals (Jinan Univ. pathway) $0.67M Y1 → $91.8M Y6
  • GCC / MENA region $0.25M Y1 → $26.3M Y6
What P1 Feeds →
→P2: Consumer demand proof unlocks B2B ingredient buyer confidence and accelerates offtake contracts
→P3: Real-world dosage + efficacy data accelerates ethics-approved clinical trial design and endpoint selection
→P4: First-party consumer behavioural data is the most commercially valuable input to the Intelligence platform
PILLAR 02
Bioactive Ingredients & B2B Systems
65–75%
Gross Margin
$3.5M
Y3 US Revenue
$60M+
Y6 Global Target

The highest-margin pillar, unlocked by P1 proof and activated progressively from Y2. Ingredient supply to global brands seeking validated NZ bioactives. PolySure™-certified matrices, Kiwifruit Bioactive Honey Matrix, and fermentation-ready formulations provide the initial IP moat — but PolySure™ is explicitly the first of multiple planned proprietary methodologies. With capital, MPL is positioned to develop additional analytical frameworks, certification standards, and protective IP moats across bioactive characterisation, stability testing, and formulation science. The architecture is designed so that no single methodology is the entire business — multiple complementary IP standards create a compound competitive barrier that grows more defensible over time. Contracted, predictable revenue with natural upsell to co-development and licensing.

Revenue Channels & Margin
  • Bulk ingredient offtake (US brands) Pilot Y2 → Material Y3
  • Co-development partnerships (functional foods) Milestone + royalty structures
  • PolySure™ CoA-certified ingredient supply ISO 17025 premium pricing
  • Asia ingredient markets (Korea, Japan, China) Premium purity positioning
  • European ingredient markets (EU/UK functional food & pharma) EFSA-aligned, ESG procurement demand
  • White-label + private label supply Scale volumes, recurring
What P2 Feeds →
→P3: B2B partner formulations generate co-funded research and co-investment in clinical validation
→P4: Every batch CoA, formulation and application type adds to PolySure™ bioactive database — the core IP asset
→P1: B2B credibility increases DTC brand authority and enables retailer entry (Whole Foods, H Mart, etc.)
PILLAR 03
Research, Clinical & Translational Science
Grant-led
Primary Funding Model
8+ years
Continuous R&D
10+
Formal Research Projects

The IP generation engine and claims defensibility layer — and the foundation of MPL's long-term licensing and royalty thesis. Not primarily a revenue pillar in the near term; it is a valuation multiplier and a durable competitive moat builder. Ethics-approved human trials across sports performance, gut health, and immune support underpin commercial claims, but the scope extends significantly further.

MPL's research programme is explicitly international in both collaboration and funding architecture. Active partnerships — including BSI/AgResearch SSIF Flagship 2 (A29556, A30172), MPI Māori Agribusiness Innovation Fund, and Jinan University (China) — are the first layer of a deliberate strategy to embed MPL's science into global research ecosystems. International funding pathways include MBIE Catalyst Fund (international science collaboration), EU Horizon-adjacent programmes via European ingredient partners, and bilateral research investment through MFAT trade and science diplomacy channels.

The longer-term clinical and biomedical horizon is significant. As polyphenol characterisation deepens through P3 and the PolySure™ platform scales, MPL is positioned to contribute to — and profit from — biomedical research at the molecule synthesis level. Specific polyphenols identified and validated through LC-HRMS/UPLC untargeted metabolomics may represent novel bioactive molecules with pharmaceutical application. This creates a potential pharma licensing pathway: where validated bioactive fractions or isolated compounds are licensed to pharmaceutical partners for drug discovery, nutraceutical-pharma hybrid development, or prescription-grade functional nutrition. Each clinical dataset, each published trial, and each metabolomics output is a licensable IP asset with an independent commercial life beyond MPL's own products.

Funding Architecture
  • BSI / AgResearch SSIF Flagship 2 Active — Contracts A29556 & A30172
  • MPI Māori Agribusiness Innovation Fund Active — Project 2024INV041
  • MBIE / Callaghan Catalyst Funds Pipeline — 12–24 months
  • He Ara Whakahihiko Capability Fund Application — Y1
  • Commercial co-investment (B2B partners) Y3+ scale
What P3 Feeds →
→P1: Clinical outcomes enable premium label claims, reduce CAC, support retailer and physician channel entry
→P2: Science credibility is a B2B sales asset — large CPG brands require evidence-backed ingredient partners
→P4: Trial datasets, metabolomics outputs, and mechanistic biology data are irreplaceable platform IP assets
PILLAR 04
Bioactive Intelligence & Predictive Platform
10–20×
Valuation Multiple (vs CPG 3–5×)
100+
Varieties in PolySure™ DB
SaaS+
Revenue Model (Y4+)

The valuation transform layer. MPS PolySure™ is a globally unique LC-HRMS/UPLC polyphenol quantification platform with ISO 17025 accreditation. Kete Rāraunga adds Māori data sovereignty infrastructure (ABS-aligned, FPIC-compliant) — a globally novel IP category. As data volume crosses critical mass, the platform enables AI-driven predictive formulation: given target health outcome + available bioactive inputs → optimal formulation. This is the SaaS/licensing layer that shifts the entire company from CPG to data platform multiples.

The global application of P4 extends far beyond ingredient certification. Kete Rāraunga and the Cultural Life Cycle Assessment (C-LCA) framework — co-developed with BSI/AgResearch and Te Kōtuku — represent a globally applicable governance and data sovereignty model for indigenous-led biological resources. In a world of tightening ABS (Access and Benefit Sharing) obligations, ESG procurement mandates, and increasing scrutiny of bioprospecting, MPL's frameworks are early infrastructure for a global regulatory shift. These frameworks are licensable to sovereign governments, indigenous organisations, and multinational corporations navigating indigenous IP obligations on every continent.

The intelligence architecture extends across the entire value chain — upstream as well as downstream. Cropping data, plantation management, environmental monitoring, and land-use intelligence feed into the platform, enabling AI-driven insights that optimise bioactive yield at source. Plantation and hive-site data informs where, when, and how to harvest for peak polyphenol expression. Environmental datasets — soil composition, climate variability, floral diversity — become predictive inputs for bioactive profile modelling. This creates a system that is not merely reactive (measuring what was produced) but predictive (directing what should be grown, where, and under what conditions). The long-term dataset ambition is significant: beginning with 100+ NZ honey varieties, the platform is architected to scale into tens of thousands of bioactive profiles across geographically diverse indigenous plant and biological resources globally — not limited to NZ or Māori — encompassing undervalued indigenous botanicals, traditional medicine systems, and endemic biological resources worldwide that have historically lacked the analytical infrastructure to realise their commercial value.

Platform Revenue Streams (Y4+)
  • PolySure™ licensing to ingredient suppliers Global SaaS-style licensing
  • Predictive formulation-as-a-service API / platform access fees
  • Kete Rāraunga data governance licensing Novel — globally unique IP
  • AI ingredient discovery co-development Revenue share + milestone
  • C-LCA / provenance certification services Regulatory compliance premium
What P4 Feeds →
→P1: Predictive formulation accelerates NPD, reduces R&D cost, improves efficacy hit rate
→P2: Data-validated ingredient specifications command category-defining premium pricing and de-risk buyer due diligence
→Valuation: Platform data assets shift the entire company multiple — all four pillars valued on data/IP multiples at exit
Pillar Resilience & Leverage Architecture

Independent Floors.
Compounding Ceilings.

Each pillar is designed to stand alone as a commercially viable business. When pillars operate in combination, they accelerate each other. This section maps both the floor (what each pillar delivers in isolation) and the ceiling (what integration unlocks) — and addresses directly what happens if any pillar underperforms.

The Design Principle: Staged Independence
The four pillars were deliberately sequenced so that earlier-stage pillars (P1, P2) are commercially self-sufficient before later-stage pillars (P3, P4) are required to generate returns. P1 generates revenue from day one. P2 activates from P1 traction — but P1 does not require P2 to succeed. P3 is substantially grant-funded, not commercial-capital-dependent. P4 builds on the data infrastructure created by P1–P3, but the company does not require P4 to achieve a strong exit — it is the upside architecture, not the base case.
Acknowledged Risk: Integration Creates Dependency
A sophisticated financial reader will correctly observe that the cross-pillar leverage described in this document also creates cross-pillar exposure. If P3 clinical trials produce null results, P1 and P2 premium pricing is partially undermined. If P4 never reaches critical data mass, the valuation multiple thesis weakens. These risks are real and are addressed directly in the stress-test scenarios below — with the structural mitigant that each pillar retains a standalone commercial floor regardless.
P1 — CPG Consumer
LiquidFuel · LiquidGold · GI-PRO
Standalone Floor — P1 in isolation
A premium nutraceutical CPG brand with WADA/HASTA certification, NZ provenance, PolySure™ polyphenol guarantee, and elite sport ambassador endorsement. This is a fully viable, independently exiteable business at $10–30M revenue. Comparable exits: Optimal Nutrition (acquired), Musclepharm (listed), EHPlabs (PE-backed). Floor exit multiple: 3–5× revenue. No dependency on P2, P3, or P4 to achieve this outcome. Critically, P1 is not a static SKU range — a continuous NPD pipeline across human health, lifestyle, sports, GLP-1 adjacent metabolic products, and high-growth animal health categories means the addressable revenue base expands structurally over time, independent of platform maturation. Each new product category launched deepens consumer data, widens the PolySure™ certification footprint, and increases the standalone brand valuation floor.
Integration Ceiling — what P2/P3/P4 add
P2 activates physician and retailer channels. P3 enables label claims that justify 30–50% price premium and open regulated health channels (Whole Foods, H Mart, pharmacy). P4 accelerates NPD and improves hit rate. Together: margin expansion from ~58% to 65%+, plus channel breadth that CPG-only brands cannot access.
If P1 underperforms
P2 B2B can be led independently — ingredient buyers do not require consumer velocity proof. P3 grant funding is non-contingent on P1 revenue. Amazon FBA provides real-time demand signal to pivot SKU or market focus without capital-intensive retail commitments.
P2 — B2B Ingredients
PolySure™ Ingredient Supply · Co-Development
Standalone Floor — P2 in isolation
A specialty bioactive ingredient platform with ISO 17025-accredited CoA certification, 100+ NZ honey varieties characterised, and a growing suite of proprietary IP methodologies. PolySure™ is the first and most developed — but not the only — analytical standard in development. With capital allocation, MPL is positioned to create multiple complementary IP methodologies across bioactive stability testing, formulation compatibility profiling, and novel compound characterisation. Each new standard adds an independent protective moat; the combined effect is a compound barrier to competitive replication that grows more defensible as the IP portfolio widens. Standalone comps: Marinova (fucoidan IP), Comvita B2B, Spherix ingredient platforms. 65–75% gross margin. Floor exit: 5–8× on contracted ingredient revenue, rising as the IP portfolio deepens. No consumer brand required.
Integration Ceiling — what P1/P3/P4 add
P1 consumer traction reduces B2B sales cycle from 12–18 months to 3–6 months (demonstrated demand de-risks buyer). P3 clinical outcomes enable B2B buyers to make health claims on their own products — a significant pricing premium. P4 data intelligence allows MPL to offer formulation prediction services as a B2B value-add, shifting from ingredient supplier to ingredient intelligence partner.
If P2 is slow to activate
P1 revenue funds operations independently. Pre-existing formulation relationships and pilot supply agreements provide early offtake. BSI/AgResearch partnerships provide credibility signals that substitute for commercial B2B proof in early conversations with ingredient buyers.
P3 — R&D / Clinical Science
PolySure™ Science · Clinical Trials · IP
Standalone Floor — P3 in isolation
P3 is the only pillar not primarily funded by commercial capital — substantially grant-funded through BSI/AgResearch SSIF Flagship 2, MPI Māori Agribusiness Innovation Fund, and forthcoming MBIE/Callaghan instruments. P3 can continue operating through commercial downturns without drawing on investor capital. Beyond grant sustainability, 8+ years of continuous R&D has created an international science infrastructure — formal collaborations spanning New Zealand, China (Jinan University), and emerging European and North American research partnerships — that is increasingly self-reinforcing. Published outputs establish MPL's science credibility in the global literature, which in turn attracts further international collaboration and co-funding. The deeper biomedical horizon is significant: as polyphenol characterisation reaches molecular resolution, specific validated compounds may represent novel pharmaceutical candidates. Isolated bioactive fractions with demonstrated mechanistic activity in human trials are licensable assets to pharmaceutical and biotech partners pursuing drug discovery or prescription-grade functional nutrition. Each clinical trial dataset, metabolomics output, and published study is an independently licensable IP asset with commercial value beyond MPL's own product range.
Integration Ceiling — what P1/P2/P4 add
P1 consumer repeat-purchase provides dosage validation that ethics-approval processes value highly. P2 B2B partner co-investment funds incremental clinical trials beyond what grants cover. P4 intelligence platform uses P3 trial datasets as the highest-quality training data — each trial compounds the platform's predictive accuracy.
If clinical trials produce mixed or null results
PolySure™ analytical science and the honey variety database retain value independently of any single clinical outcome. Negative trial results in one indication (e.g. inflammation) do not invalidate results in others (e.g. gut health). Multi-indication trial programme structure was designed specifically to avoid single-outcome dependency. The science infrastructure itself — ISO 17025 accreditation, metabolomics capability, international research partnerships — is commercially valuable regardless of any individual trial result.
P4 — Intelligence Platform
MPS PolySure™ · Kete Rāraunga · AI Predictive
Standalone Floor — P4 in isolation
P4 is explicitly the upside architecture — it is not required for the base-case exit thesis. The company achieves a strong outcome (NZD $70M Series A, subsequent acquisition) on P1+P2+P3 alone. P4 is the mechanism that shifts the valuation ceiling from ~$200–400M (CPG/ingredient exit) to $1B+ (platform exit). The risk is timing and data mass — not commercial viability of the underlying P1–P3 business.
Integration Ceiling — what P1/P2/P3 add
P1 consumer data is the highest-quality real-world training data for predictive formulation AI. P2 batch CoA data is the structured analytical database that trains bioactive prediction models. P3 clinical outcomes provide mechanistic ground truth that validates model outputs. When all three are feeding P4 simultaneously, the platform's predictive accuracy reaches a quality that cannot be replicated by any external party without equivalent data mass — an accumulating, structural moat.
If P4 platform activation is delayed
P4 delay does not affect P1–P3 commercial operations or cash generation. PolySure™ licensing can be monetised before full AI platform activation — early licensing revenue validates the commercial model without requiring the full intelligence stack. The Kete Rāraunga framework has standalone licensing value as a data sovereignty governance tool, independent of the AI platform layer.

Scenario Stress-Test: What Breaks, What Holds

For each underperformance scenario, the table shows: what the standalone floor value remains, what the impact on overall thesis is, and what structural mitigant is already in place.

Scenario Severity Standalone Floor Remains Impact on Overall Thesis Structural Mitigant Already in Place
P1 US launch underperforms (Y1 revenue <$0.8M) Medium Korea pipeline + NZ domestic + D2C base continues. NZD revenue floor maintained. B2B activation delayed ~6 months. Amazon ranking slower to build. P4 consumer data thinner in Y1–2. Amazon FBA allows real-time SKU and pricing adjustment without capital commitment. Korea pipeline ($190K+ Y1) is already contracted and independent of US performance.
P2 B2B takes 24+ months to generate material revenue Low–Med P1 funds operations. B2B pipeline builds independently. No capital shortfall. Blended margin improvement delayed. Y3 revenue mix remains P1-dominant. Platform data from B2B thinner. P2 revenue was conservatively modelled as zero in Y1. Capital raise does not depend on Y2 B2B activation. Pre-existing formulation relationships compress sales cycle.
P3 clinical trial produces null primary endpoint (one indication) Low PolySure™ analytical science, metabolomics database, and international partnerships retain full value. That specific label claim is not available. Other indications (gut, immune, sports) unaffected. P1 premium pricing partially dependent on claims — other differentiators (PolySure™, provenance, ambassador) remain. Multi-indication trial design. 3 concurrent trial streams (sports performance, gut health, immune). Null result in one does not affect others. P3 grant funding continues regardless of individual trial outcomes.
P4 platform fails to attract paying external licensees by Y4 Medium P1+P2+P3 business remains intact. Exit thesis on CPG/ingredient basis (3–8×) still valid. NZD $70M Series A achievable on P1–P3 alone. Valuation ceiling compressed. 10–20× multiple thesis weakens. Platform exit pathway closes; acquisition or ingredient roll-up becomes primary exit. Platform activation is upside, not base case. PolySure™ licensing to external parties can be initiated from Y2 without full AI stack — early proof of licensing model. Kete Rāraunga has standalone licensing value independent of AI layer.
Key grant (SSIF Flagship 2 or MPI) is not renewed Medium P1 and P2 commercial revenue continues unaffected. PolySure™ analytical capability is in-house — does not require ongoing grant funding to operate. P3 pace slows. Clinical trial timelines extend. IP generation rate reduces. P4 data substrate accumulates more slowly. Multi-agency grant ecosystem (TPK, MPI, MBIE, Callaghan) — no single grant is existential. He Ara Whakahihiko, AGMARDT, and MBIE Catalyst Fund applications are concurrent and complementary. B2B partner co-investment in clinical trials provides commercial grant alternative from Y3.
Macro: global nutraceutical market softens significantly Medium B2B ingredient supply (P2) is counter-cyclical to CPG — ingredient buyers often increase private-label activity in downturns. P3 grant income is non-cyclical. P1 consumer revenue growth slows. CAC increases. Amazon competitiveness intensifies. Revenue diversification across USA, Korea, China, GCC reduces single-market exposure. B2B provides counter-cyclical revenue floor. Premium provenance + PolySure™ differentiation protects pricing in a commoditising market.
Revenue Architecture

Stacked Revenue Model by Pillar

Conservative US-only model years 1–3, expanding to global six-year platform. Pillar contributions shown with gross margin profiles. Revenue is cumulative, not sequential — pillars stack, they don't replace each other.

// YEAR 1 — LAUNCH & PROOF
$1.5M
USD · US Market Only · Conservative
P1 — Amazon FBA (60% rev mix Y1) $0.9M60%
P1 — D2C Own Platform (40% rev mix Y1 · 58–78% GM) $0.6M40%
P2 — B2B (not activated) $0
P3 — Grant-funded (no rev) —
EBITDA (Conservative) $252K
// YEAR 2–3 — SCALE & B2B ACTIVATION
$5M → $10M
USD · US + Korea + China · Conservative
P1 — Amazon $2.4M → $3.9M39–48%
P1 — D2C $1.6M → $2.6M26–32%
P2 — B2B Ingredients $1.0M → $3.5M20–35%
P3 — Grant co-funded Non-dilutive
EBITDA Y3 $2.38M (23.8%)
// YEAR 6 — GLOBAL PLATFORM SCALE
$373M
USD · USA + Korea + China + GCC · 6yr Target
P1 — USA CPG (all channels) $235M63%
P1 — Korea + China + GCC $138M37%
P2 — B2B Global Ingredients $60M+est.
P4 — Platform / Licensing $15M+SaaS/Lic.
Platform Value (10–20× IP) $3.7B – $7.4B

Cost & Margin Profile by Pillar

Pillar Revenue Type COGS Drivers Gross Margin EBITDA Margin (Mature) Multiple at Exit
P1 — CPG / Consumer Product sales, subscriptions, bundles Honey inputs, manufacturing, logistics, HASTA/WADA testing, Amazon fees (~35%), marketing CAC ~58% (validated) 16–24% at scale 3–5× (CPG) → uplift via brand premium
P2 — B2B Ingredients Contracted bulk supply, co-dev, CoA services Honey inputs, analytical testing, minimal marketing (contract-driven), certification overhead 65–75% 35–50% at scale 5–8× (ingredient platform)
P3 — R&D / Science Grant income, co-investment, eventual royalties Scientist FTE, analytical infrastructure, trial costs. Largely offset by non-dilutive grant funding N/A (investment phase) Negative (strategic) IP royalties → 8–15× on clinical IP
P4 — Intelligence Platform Licensing fees, SaaS subscriptions, data partnerships, API access Platform infrastructure, data science FTE, compliance. Low per-unit marginal cost. 80–92% (SaaS model) 50–70% at maturity 10–20× (data / IP platform)
Blended (Early Scale) Multi-channel, multi-pillar Scaling operations, marketing, R&D reinvestment ~60%+ ~23–28% 8–15× blended
Capital Value Architecture

Valuation by Stage & Structure

Valuation is not a single number — it is a trajectory shaped by which pillars are operational, what data assets are accumulated, and which multiple regime the company has transitioned into. This section maps the progression.

Current / Near-Term
Seed / AIP Growth Round
NZD $10–15M
Pre-money valuation range · Y1
P1 activation proven (NZ export + Korea delivery + Amazon pipeline). P2 seeded. P3 grants active (SSIF Flagship 2, MPI). P4 architecture documented. Raise: NZD $5M under AIP Growth Category. Capital deploys into US market entry and manufacturing scale.
Multiple basis: CPG early-stage + grant-backed R&D premium
18–24 Month Horizon
Series A — Platform Validation
NZD $70M
Target valuation · 18–24 months
US revenue established ($5–10M run-rate). Korea and China pipeline generating. B2B ingredient contracts in place. PolySure™ database at critical mass. Kete Rāraunga Phase 1 complete. Clinical trial data published. Valuation shifts from pure CPG toward blended CPG + data platform multiple. Raise: USD $2.5M Series A.
Multiple basis: 7–10× blended (CPG + early data platform)
Mid-Term Horizon
Series B / Pre-Exit Platform
USD $500M–$1B+
Platform-scale valuation thesis
All four pillars operating. Global revenues $50–150M+ run-rate. PolySure™ licensing in multiple markets. Kete Rāraunga — the Māori data sovereignty and governance framework — established as globally unique indigenous IP infrastructure, generating licensing revenue from sovereign governments, multinational corporations, and indigenous organisations navigating ABS obligations. Clinical IP generating royalty streams. P4 AI platform with paying SaaS customers. Positioned for strategic acquisition by major CPG (Nestlé Health Science, Kerry Group, DSM-Firmenich, IFF) or NZX/ASX IPO.
Multiple basis: 10–20× data/IP platform

The Multiple Transition Mechanism

The central commercial thesis is the transition from CPG multiples (3–5×) to data/IP multiples (10–20×). This is not aspirational — it is structural, and happens through the systematic accumulation of:

  • ◈ PolySure™ database crossing 100+ varieties with validated formulation outcomes
  • ◈ Published clinical trial data establishing mechanistic evidence for label claims
  • ◈ Kete Rāraunga formalised as a globally novel indigenous data sovereignty framework
  • ◈ First paying PolySure™ licensing or platform subscribers outside MPL
  • ◈ AI-generated formulation recommendations validated by real-world outcomes

Strategic Acquirer Profile

The company is architected to be strategically attractive to multiple buyer categories:

  • → Global CPG Majors (Nestlé Health Science, Reckitt, Church & Dwight) — acquire validated science + brand
  • → Specialty Ingredient Platforms (DSM-Firmenich, IFF, Kerry, Givaudan) — acquire PolySure™ + database
  • → Asian Distribution Partners (Dongwon, CJ CheilJedang, CITIC) — acquire NZ provenance + access rights
  • → AgriFood Tech Investors (Temasek, ADM Capital) — acquire bioactive intelligence platform
Capital Realisation

Off-Ramps & Value Realisation Pathways

The architecture is designed with optionality — multiple validated pathways to capital realisation at different stages and scales, preserving founder and investor flexibility.

Exit Pathway A
Strategic Acquisition — Whole Company
USD $300M – $700M+
Full acquisition by a global CPG or specialty nutrition major. The acquirer buys the validated brand (P1), the ingredient infrastructure (P2), the clinical IP (P3), and the intelligence platform (P4) as a package. Precedent: Blackmores acquired by Kirin (USD $1.5B, 2022); Vitaco acquired by Shanghai Pharmaceuticals. MPL is positioned similarly but with significantly stronger data moat and Māori provenance differentiation. Target window: platform maturity at $50M+ revenue run-rate.
TARGET WINDOW → Y4–Y6 · TRIGGER: $50M+ revenue + platform activation
Exit Pathway B
PolySure™ IP Licensing Roll-Up
USD $50M – $200M
Stand-alone licensing of the PolySure™ polyphenol quantification platform and associated IP to ingredient suppliers, food manufacturers, and wellness brands globally. This can be structured as a partial exit — spinning out the IP licensing entity as a separate vehicle while retaining CPG operations. Licensing SaaS economics: 80–90% gross margin, highly predictable recurring revenue, global scalability with zero incremental COGS. Precedent: Marinova's fucoidan IP licensing model; Evolva's fermentation biosynthesis platform.
TARGET WINDOW → Y3–Y5 · TRIGGER: 10+ paying licensees globally
Exit Pathway C
NZX / ASX / NASDAQ Listing
Market cap USD $500M – $2B
Public market listing at appropriate scale, positioning as a globally unique bioactive intelligence and Māori-led innovation company. NZX provides domestic alignment with New Zealand provenance story; ASX or NASDAQ accesses deeper liquidity and international investor appetite for data/IP growth companies. The Māori-led, indigenous innovation, data sovereignty angle is a genuinely novel institutional investor narrative in the near-term horizon. Requires: audited multi-year revenues, governance structure, and platform activation proof. IPO does not preclude subsequent acquisition.
TARGET WINDOW → Y5–Y7 · TRIGGER: $100M+ revenue, platform data assets audited
Exit Pathway D
Division-Level Partial Exits
Multiple events · USD $20M – $150M each
The four-pillar architecture creates natural division-level exit optionality: (1) Sell or JV the B2B Ingredients division to a global ingredient platform (DSM-Firmenich, Kerry) retaining CPG; (2) Spin off the Bioactive Intelligence platform as a separate technology company with its own cap table; (3) Sell the Korea / Asia distribution rights to a regional partner while retaining global IP; (4) License the Kete Rāraunga framework to sovereign governments or indigenous organisations globally as a standalone asset. Each pillar has its own valuation floor and exit logic.
AVAILABLE CONTINUOUSLY → Structurally enabled from Y2 onward
Compounding Mechanics

The Value Flywheel

Why this architecture self-reinforces rather than merely growing linearly. Each revolution of the flywheel makes the next revolution cheaper and faster.

01
Consumer demand validates bioactive efficacy
Amazon and D2C launch generates repeat purchase data — a signal CPG companies spend tens of millions to manufacture. MPL generates it as a byproduct of commercial operations. Every subscription renewal is an unstructured clinical data point on efficacy.
02
B2B demand scales a globally unique bioactive database
Every B2B partner requiring batch-certified CoAs generates a new data point in the PolySure™ database. The current 100+ NZ honey variety dataset is the beginning, not the ceiling. The platform is architected to scale into tens of thousands of bioactive profiles — geographically distributed across indigenous and endemic biological resources worldwide. NZ Māori honey varieties are the founding dataset; the model extends to undervalued indigenous botanicals, traditional medicine systems, endemic plant species, and biological resources across the Pacific, Southeast Asia, South America, Africa, and beyond. Communities and regions that have historically lacked the analytical infrastructure to quantify and commercialise their biological resources become potential data partners, licensees, and co-beneficiaries. The dataset becomes a global bioactive intelligence commons — proprietary, governed, and commercially significant in a way no competitor can replicate without decades of equivalent investment.
03
Science outcomes increase claim territory
Each published clinical outcome (gut health, sports performance, immune) expands the legally defensible claim territory for P1 products and increases the premium that P2 ingredient buyers will pay for association with the evidence base.
04
Data mass enables predictive AI formulation
Once the combined dataset from P1 + P2 + P3 reaches critical mass, the Intelligence Platform generates formulation predictions that compress new product development from 24 months to 6 months. Speed of innovation becomes structurally faster than competitors.
05
Platform value shifts the multiple — permanently
When external companies begin licensing PolySure™ or accessing the Intelligence Platform, MPL ceases to be valued as a CPG company. Every dollar of SaaS/licensing revenue is worth 3–5× more than product revenue in a DCF, and attracts technology-class acquirers rather than CPG acquirers — a fundamentally larger pool of strategic buyers.
06
Higher multiple attracts better capital — at lower dilution
A company valued at 10–20× attracts Tier 1 institutional capital (Temasek, SoftBank Vision, Baillie Gifford, major agrifood strategics) rather than growth-stage CPG funds. This capital is both cheaper (lower dilution) and strategically more valuable (market access, distribution, validation). The flywheel compounds.
BIOACTIVE PLATFORM VALUE P1 CPG & Consumer P2 B2B Ingredients P3 R&D & Science P4 Intelligence Platform PolySure™ · Kete Rāraunga · C-LCA

Circular value creation: every pillar feeds every other pillar.
Platform value accumulates at the convergence centre.

Investment Thesis

The Unicorn Thesis

Why this architecture, if executed, is capable of producing a unicorn-scale outcome — and why the specific combination of assets is structurally inimitable.

"We are not a honey company. We are building a bioactive intelligence asset that happens to generate CPG cashflow while it does so."

The commercial thesis rests on a specific and unusual structural insight: the CPG revenue stream is not the destination — it is the capitalisation mechanism for building a data and IP platform that achieves an order-of-magnitude better valuation multiple.

Traditional honey or nutraceutical companies reach a ceiling at $50–200M exits because they are valued as brands + manufacturing. MPL's architecture breaks this ceiling by accumulating data, IP, and platform infrastructure in parallel with commercial revenue growth — so that when exit windows open, the valuation basis has already shifted.

The three structural moats are individually strong and collectively irreplicable: (1) PolySure™ takes 8+ years of analytical work to replicate; (2) Kete Rāraunga is globally unique and protected by indigenous IP frameworks; (3) The 8-year continuous R&D investment and 10+ formal research projects are a compounding head start no new entrant can buy their way into.

Competitive Moat Comparison

Capability Typical Nutraceutical Brand Mānuka Performance
Polyphenol quantification IP Third-party lab (no IP) ✓ Proprietary PolySure™ ISO 17025
Indigenous data sovereignty None ✓ Kete Rāraunga — globally unique
WADA/HASTA certified products Few (expensive process) ✓ All batch-tested products
Active clinical trials Rarely ✓ Gut, sports, immune (ethics-approved)
Government research partnerships Rare ✓ BSI/AgResearch, MPI, MBIE
AI predictive formulation platform None ✓ In development (P4)
Multi-country FTA export advantage Some ✓ NZ FTAs: USA, Korea, China, India
Elite sport ambassador validation Influencers only ✓ All Blacks 7s, Black Ferns, Logan Tom
B2B ingredient + CPG dual engine Usually one or other ✓ Designed from founding
Valuation multiple transition path CPG ceiling 3–5× ✓ Structural path to 10–20×
Key Risks & Mitigants
  • Market entry speed risk: Mitigated by Amazon FBA (day-1 US distribution access) and existing Korea pipeline.
  • Platform activation timing: Mitigated by grant-funded P3 running in parallel — P4 builds on P3 outputs regardless of P1/P2 pace.
  • Supply chain concentration: Franklin district manufacturing hub (South Auckland) identified; Waikato-Tainui partnership strengthens supply resilience.
  • Claims regulatory risk: ISO 17025 + clinical programme is the compliance infrastructure; PolySure™ CoAs de-risk label claims globally.
  • Capital concentration risk: Multi-agency grant ecosystem (TPK, MPI, MBIE, NZTE) plus AIP Growth Capital reduces single-source dependency.